Riskpilot← Back to searchSign inGet full accessWELAMED AB
ABActiveOrg 5592715915Första Avenyen 8General medical practice activities · NACE 8621Est. 20201 employees
Revenue 2024
SEK 208K
+1% vs 2023
EBITDA margin
42.3%
+42% vs 2023
Equity ratio
47.8%
Financial strength
Net profit 2024
SEK 88K
-76% vs 2023
| Revenue | SEK 208K | +1% |
| EBITDA | SEK 88K | +42% |
| Net profit | SEK 88K | -76% |
| Total assets | SEK 3,2M | -26% |
| Equity | SEK 1,5M | +6% |
| Employees | 1 | — |
Legal name
WELAMED AB
Org number
5592715915
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
15 september 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är medicinsk konsultation, fastighetsförvaltning, förvaltning och handel med värdepapper och därmed förenlig verksamhet.
Address
Första Avenyen 8
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 206 | 208 |
| Staff expenses | — | — | — | — |
| EBITDA | −12 | — | 62 | 88 |
| Depreciation & amort. | −0 | −0 | −115 | −115 |
| EBIT | −12 | 0 | −53 | −27 |
| Net financials | −16 500 | — | 418 | 115 |
| Profit before tax | 988 | 0 | 365 | 88 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | 988 | 0 | 365 | 88 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 4 996 | 4 678 | 4 283 | 3 154 |
| Equity | 1 013 | 1 013 | 1 421 | 1 509 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 3 983 | 3 666 | 2 862 | 1 644 |
| Total debt | 3 983 | 3 666 | 2 862 | 1 644 |
EBITDA margin
42.3%
This company
15.8%
Market median
+168% vs market
20212024
Equity ratio
47.8%
This company
38.2%
Market median
+25% vs market
20212024
Return on equity
5.8%
This company
18.4%
Market median
-68% vs market
20212024
Net profit margin
42.3%
This company
8.1%
Market median
+422% vs market
20212024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20212024
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of WELAMED AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Axel Gunnar Welander | Board of Directors | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Carl Emil Symreng | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |